Citations

Clear

1792 citation(s) found for "Stephanie".

Abstract 12480: Establishing Safety and Risk Profile of Right Heart Catheterization
Hull, Jocelyn V., Hajj, Stephanie C. El , Lennon, Ryan J. , Crusan, Daniel J. , Gulati, Rajiv , Kanwar, Amrit , Farhat, Salman , Sabbagh, Abdallah El , Singh, Mandeep , Padkins, Mitchell , Hajj, Stephanie C. El , Al‐Hijji, Mohammed , Behfar, Atta , Jain, Vaibhav

Mayo Clinic

Circulation | April 23, 2024 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.12480 Get It

Introduction: We aim to elucidate the incidence of major complications related to right heart catheterization (RHC) and ascertain if there are unique risks with right ventricular biopsy. Methods: Diagnostic RHC procedures from 1/1/2002 through 12/31/2013 were identified using the clinical scheduling system at Mayo Clinic, Rochester. Major complications were identified through electronic records using International Classification of Diseases, Ninth Revision billing codes. All events were recorded and adjudicated. Analysis was performed on four separate patient categories (RHC/RV angiography alone, RV biopsy alone, multiple RHC procedures, and concurrent RHC/LHC procedures) and the overall group. Primary outcomes are described in Table 1. Outcomes were measured within 7 days of the procedure, except for death (same day events) and tricuspid regurgitation (variable time endpoints). Results: There were 17,696 RHC procedures (5,556 RHC/RV angiography, 3,846 RV biopsy alone, 776 multiple RHC procedures, and 7,518 combined RHC/LHC). Patient population had a mean age of 56.5 years (15.3) and was predominantly male (58.5%). Same-day death related to RHC procedure occurred in 1 procedure or 0.6 of 10,000 RHCs. There was no significant difference in the risk of complications across RHC procedure categories except for worsening tricuspid regurgitation, which was significantly (p<0.001) more prevalent with RV biopsy (392 cases, 6.0%) than without (136 cases, 1.2%). Conclusion: The incidence of major complications related to right heart catheterization is rare. Worsening tricuspid regurgitation is the most frequently identified change with a significantly higher prevalence with biopsies.
Democratizing Artificial Intelligence in Anatomic Pathology
Flotte, Thomas J. , Derauf, Stephanie A., Byrd, Rachel K., Kroneman, Trynda, Bell, Debra A., Stetzik, Lucas, Lee, Seung‐Yi , Samiei, Alireza, García, Joaquín J. , Beamer, Gillian , Kroneman, Trynda N, Hart, Steven N. , Westerling-Bui, Thomas

Mayo Clinic

Archives of Pathology & Laboratory Medicine | April 22, 2024 | Volume: 149 | Issue: 1 | Pages: 55-59

10.5858/arpa.2023-0205-oa | PMID 38649149 Get It

Context.— Artificial intelligence is a transforming technology for anatomic pathology. Involvement within the workforce will foster support for algorithm development and implementation. Objective.— To develop a supportive ecosystem that enables pathologists with variable expertise in artificial intelligence to create algorithms in a development environment with seamless transition to a production environment. Design.— Platform requirements included (1) approachable and intuitive user interface, (2) diverse algorithmic modeling options, (3) support capability for internal and external collaborations, (4) a seamless mechanism for discovery to clinical deployment transition, (5) the ability to meet minimum institutional requirements for information technology (IT) review, and (6) the ability to be scalable over time. The ecosystem required platform education, data science guidance, project management structure, and ongoing leadership. Results.— The development team considered internal development and vended solutions. Because of the extended timeline and resource requirements for internal development, a decision was made to use a vended solution. Vendor proposals were solicited and reviewed by pathologists, IT, and security groups. A vendor was selected and pipelines for development and production were established. Proposals for development were solicited from the pathology department. Eighty-four investigators were selected for the initial cohort, receiving training and access to dedicated subject matter experts. A total of 30 of 31 projects progressed through the model development process of annotating, training, and validation. Based on these projects, 15 abstracts were submitted to national meetings. Conclusions.— Democratizing artificial intelligence by creating an ecosystem to support pathologists with varying levels of expertise can break down entry barriers, reduce overall cost of algorithm development, improve algorithm quality, and enhance the speed of adoption.
0480 Less Is More? A Study Comparing Outcomes Between 4% vs 3% Hypopnea Scoring Rules
Tu, Xinhang, Baughn, Julie , Herold, Daniel L. , Reckward, Dennis, Fenske, Chris, Brown, Jennifer R. , Becker, Stéphanie , Erickson, Melanie, Tu, Xinhang , Morgenthaler, Timothy I. , Becker, Stephanie, Lipford, Melissa C.

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A206-A207

10.1093/sleep/zsae067.0480 Get It

Abstract Introduction The definition of respiratory events has evolved over decades. The current American Academy of Sleep Medicine scoring manual recommends hypopneas be defined by a ≥ 30% airflow reduction with either ≥ 3% desaturation or an arousal, while the prior “recommended” criteria of a ≥ 30% airflow reduction and associated ≥ 4% oxygen desaturation (with no requirement of arousal) was changed to “optional”. Consequently, events previously characterized as a respiratory effort related arousal (RERA) may now be defined as a 3% hypopnea. We hypothesized that while the 3% apnea-hypopnea index (3%AHI) will be higher than the 4%AHI, the 3%AHI will be similar to the 4% respiratory disturbance index (4%RDI), and that the measurement of RERAs under 3% scoring criteria will be clinically insignificant. Methods We prospectively collected 70 consecutive in-lab polysomnography results in 4 adult age groups. We re-scored the respiratory events utilizing the 3% hypopnea rule, and compared the differences between 3% and 4% scoring criteria. Results Among the 70 studies (mean age 50, males 46%), the 3%AHI was significantly higher than the 4%AHI (+9.247 ± 1.161, p&lt; 0.001). This was mainly due to increased hypopnea events (+10.313 ± 1.617, p&lt; 0.001). The 3%AHI was significantly different from the 4%RDI (+7.096 ± 1.133, p&lt; 0.001). There were no significant differences between the 3% and 4% RERA indices, with both values being minimal. Results were similar in both diagnostic and titration phases of testing. Conclusion As previously shown, utilizing the 3% hypopnea rule results in an increased AHI. Most of this difference is related to hypopneas with negligible influence of RERAs. This may lead to increased diagnosis and severity of sleep-disordered breathing in the adult population, and potentially be associated with payer ramifications. Our findings demonstrated negligible RERA indices on average with either rule, thus calling into question the clinical significance of this index in most patients. Support (if any) NA
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
DiNardo, Courtney D. , Roboz, Gail J. , Watts, Justin M. , Madanat, Yazan F. , Prince, Gabrielle T., Baratam, Praneeth , Botton, Stéphane de , Stein, Anthony S. , Foran, James M. , Arellano, Martha , Sallman, David A. , Marchione, Dylan M. , Patel, Prapti A. , Kapsalis, Stephanie M., Garcia‐Manero, Guillermo , Fathi, Amir T. , de Botton, Stéphane , Fathi, Amir T , DiNardo, Courtney , Roboz, Gail J , Madanat, Yazan , Hossain, Mohammad Sharif , Bai, Xiaofei

Mayo Clinic

Blood Advances | April 19, 2024 | Volume: 8 | Issue: 15 | Pages: 4209-4220

10.1182/bloodadvances.2023012302 | PMID 38640348 Get It

Abstract Ivosidenib is a first-in-class mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor with efficacy and tolerability in patients with advanced mIDH1 hematologic malignancies, leading to approval in frontline and relapsed/refractory (R/R) mIDH1 acute myeloid leukemia. We report final data from a phase 1 single-arm substudy of once-daily ivosidenib in patients with R/R mIDH1 myelodysplastic syndrome (MDS) after failure of standard-of-care therapies. Primary objectives were to determine safety, tolerability, and clinical activity. The primary efficacy end point was the complete remission (CR) + partial remission (PR) rate. Nineteen patients were enrolled; 18 were included in the efficacy analysis. Treatment-related adverse events occurred in 8 (42.1%) patients, including a grade 1 QT interval prolongation in 1 (5.3%) patient and grade 2 differentiation syndrome in 2 (10.5%) patients. Rates of CR + PR and objective response (CR + PR + marrow CR) were 38.9% (95% confidence interval [CI], 17.3-64.3) and 83.3% (95% CI, 58.6-96.4), respectively. Kaplan-Meier estimates showed a 68.6% probability of patients in CR achieving a remission duration of ≥5 years, and a median overall survival of 35.7 months. Of note, 71.4% and 75.0% baseline red blood cell (RBC)- and platelet-transfusion-dependent patients, respectively, became transfusion independent (TI; no transfusion for ≥56 days); 81.8% and 100% of baseline RBC and platelet TI patients, respectively, remained TI. One (5.3%) patient proceeded to a hematopoietic stem cell transplant. In conclusion, ivosidenib is clinically active, with durable remissions and a manageable safety profile observed in these patients. This trial was registered at www.ClinicalTrials.gov as #NCT02074839.
Mind the Gap! Working Toward Gender Equity in Pediatric and Congenital Heart Disease: Present and Future
Chowdhury, Devyani , Bansal, Neha , Ansong, Annette , Baker‐Smith, Carissa M. , Choueiter, Nadine , Co‐Vu, Jennifer , Elliott, Pietro , Fuller, Stephanie , Jain, Supriya , Johnson, Jonathan N. , Karamlou, Tara , Kipps, Alaina K. , Laraja, Kristin, Rasheed, Muneera A. , Ronai, Christina , Sachdeva, Ritu , Snyder, Christopher S. , Sutton, Nicole , Stiver, Corey, Shaffer, Kenneth M. , Williams, Roberta G. , Baker-Smith, Carissa M , Co-Vu, Jennifer , Elliott, Pietro , Fuller, Stephanie , Jain, Supriya S , Jone, Pei-Ni , Johnson, Jonathan , Kipps, Alaina K , Lopez, Keila N , Rasheed, Muneera , Ronai, Christina , Sachdeva, Ritu , Snyder, Chris , Sutton, Nicole , Taggart, Nathaniel W , Shaffer, Kenneth , Williams, Roberta , Bauser‐Heaton, Holly , Lopez, Keila N. , Saidi, Arwa S. , Taggart, Nathaniel W.

Mayo Clinic

Journal of the American Heart Association | April 19, 2024 | Volume: 13 | Issue: 9 | Pages: No page available

10.1161/jaha.123.032837 | PMID 38639355 Get It

Evidence from medicine and other fields has shown that gender diversity results in better decision making and outcomes. The incoming workforce of congenital heart specialists (especially in pediatric cardiology) appears to be more gender balanced, but past studies have shown many inequities. Gender‐associated differences in leadership positions, opportunities presented for academic advancement, and recognition for academic contributions to the field persist. In addition, compensation packages remain disparate if evaluated based on gender with equivalent experience and expertise. This review explores these inequities and has suggested individual and institutional changes that could be made to recruit and retain women, monitor the climate of the institution, and identify and eliminate bias in areas like salary and promotions.
Biocompatible Cable Ties Are an Alternative to Metal Stabilizers for Bar Securement During Minimally Invasive Pectus Excavatum Repair
Raikot, Swathi R. , Polites, Stephanie F. , Potter, D. Dean

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | April 18, 2024 | Volume: 34 | Issue: 10 | Pages: 936-940

10.1089/lap.2023.0417 | PMID 38634817 Get It

Background: Bar stabilization during minimally invasive pectus excavatum repair (MIRPE) is critical to avoid dislodgement. Multiple techniques are described including stabilizers, wires, and sutures. This retrospective study compared bar movement and outcomes between existing techniques and ZipFix™, a biocompatible cable tie. Methods: Patients ≤20 years of age who underwent MIRPE with ZipFix between January 2021 and September 2022 were compared with historical controls who underwent repair by same surgeons between January 2018 and December 2020 using stabilizers or polydioxanone suture (PDS). Demographics, clinical details, and outcomes were compared using Kruskal–Wallis and chi-square tests. Results: Of the 116 patients who underwent repair, 45 had bars secured with ZipFix (39%) and 71 (61%) were historical controls (35 stabilizer, 36 PDS). Median (interquartile range) age was 15 (14–16) years and Haller index was 3.9 (3.6–4.5). Nine (8%) patients required two bars. Haller index and use of second bar were comparable between stabilization techniques ( P > .05). In total, 49 patients (40%) reported any pain at 1 month and this was similar between stabilization techniques ( P = .45). Median bar movement was greater for bars secured with PDS than with ZipFix or stabilizers at 1 month (5.5 versus 2.3 versus 3.3°, P = .010) and last follow-up (6.5 versus 2.1 versus 3.6°, P < .001). One patient whose bar was secured with PDS required revision for dislodgement. Conclusion: Pectus bar stabilization with ZipFix is a safe alternative to metal stabilizers and both techniques are superior to suture stabilization alone. The use of ZipFix may be preferred given its lower cost and ease of use.
Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human
Roh, Jason D. , Castro, Claire , Yu, Andy, Rana, Sarosh , Shahul, Sajid , Gray, Kathryn J. , Honigberg, Michael C. , Ricke‐Hoch, Melanie , Iwamoto, Yoshiko , Yeri, Ashish, Guerra, Justin Ralph Baldovino , Hobson, Ryan , Chaudhari, Vinita , Chang, Bliss , Sarma, Amy , Lerchenmüller, Carolin , Sayed, Zeina R. Al , Verdugo, Carmen Diaz , Xia, Peng , Skarbianskis, Niv, Zeisel, Amit , Kirkland, James L. , Gorcsan, John , Damp, Julie B., Hanley‐Yanez, Karen , McNamara, Dennis M. , Investigators, for the IPAC, Rosenzweig, Anthony , Fett, James D., Pisarcik, Jessica, McTiernan, Charles F. , Alharethi, Rami , Rasmusson, Kismet, Brunisholz, Kim , Butler, Amy L., Budge, D., Kfoury, Abdallah G., Horne, Benjamin D. , Tuinei, Joe, Brown, Heather , Naftilan, Allen J., Russell, Jill , Freehardt, Darla, Hsich, Eileen , Oblak, Cynthia, Ewald, Greg, Whitehead, Donna, Flanagan, Jean, Platts, Anne, Mullin, Stephanie, Givertz, Michael M. , Anello, Mary Susan, Booth, David R. , Sandlin, Tiffany, Wijesiri, Wendy, Blauwet, Lori A., Brunner, Joann, Phelps, Mary, Kempf, Ruth, Modi, Kalgi , Norwood, Tracy, Griza, Decebal Sorin, Adams, Patricia L., Thohan, Vinay , Wesley-Farrington, Deborah, Soots, Sandra, Sheppard, Richard , Lapointe, Nathalie, Nathaniel, Heather, Kealey, Angela, Semigran, Marc J., Daher, Maureen, Silber, David, Popjes, Eric , Frey, Patricia, Nicklas, Todd, Alexis, Jeffrey D. , Caufield, Lori, Thornton, John W., Gentry, Mindy, Robinson, V.J. , Sharma, Gyanendra K. , Holloway, Joan, Powell, Maria, Markham, David W. , Fernandez, Lynn, Gimovsky, Martin L., Hochbaum, Natalia, Patel, Bharati Kadamb , Adams, Laura , Ramani, Gautam , Robinson, Shawn , Fisher, Stacy D. , Marshall, Joanne, Haythe, Jennifer , Mancini, Donna , Bijou, Rachel, Marks, Marybeth, Arango, Henry, Bolos, Mariana, Mather, Paul , Rubin, Sharon, Bonita, Raphael , Eberwine, Susan, Skopicki, Hal A. , Stergiopoulos, Kathleen , McCathy-Santoro, Ellen, Intravaia, Jennifer, Maas, Elizabeth W., Safirstein, Jordan, Martinez, Nancy , Corpoin, Christine, Hesari, Donna, Chaparro, Sandra , Hudson, Laura J., Ghali, Jalal K. , Injic, Zora, Wittstein, Ilan S. , Kitchen, Robert , Guerra, Justin Baldovino , Chaudhari, Vinita , Chang, Bliss , Sarma, Amy , Al Sayed, Zeina R , Diaz Verdugo, Carmen , Xia, Peng , Zeisel, Amit , Bauersachs, Johann , Kirkland, James L , Karumanchi, S Ananth , Gorcsan, John , Sugahara, Masataka , Hanley-Yanez, Karen , Ellinor, Patrick T , Arany, Zoltan Pierre , McNamara, Dennis M , Rosenzweig, Anthony , Honigberg, Michael C , Castro, Claire , Karumanchi, S. Ananth , Ellinor, Patrick T. , Investigators, for the IPAC, Hilfiker‐Kleiner, Denise , Schelbert, Erik B. , Butler, Amy, Elkayam, Uri , Caro, Jorge , Rajagopalan, Navin , Booth, David, Cooper, Leslie T. , Briller, Joan Ellen , Felker, G. Michael , Kociol, Robb D. , Adams, Patricia, Wells, Gretchen , Michel, Caroline, Boehmer, John , Holloway, Joan, Powell, Maria, Drazner, Mark H. , Zucker, Mark Jay , Baran, David A. , Patel, Bharati, Gottlieb, Stephen S. , Farr, Maryjane , Bozkurt, Biykem , Maas, Elizabeth, Kleet, Audrey

Mayo Clinic

Science Translational Medicine | April 17, 2024 | Volume: 16 | Issue: 743 | Pages: No page available

10.1126/scitranslmed.adi0077 | PMID 38630848 Get It

Peripartum cardiomyopathy (PPCM) is an idiopathic form of pregnancy-induced heart failure associated with preeclampsia. Circulating factors in late pregnancy are thought to contribute to both diseases, suggesting a common underlying pathophysiological process. However, what drives this process remains unclear. Using serum proteomics, we identified the senescence-associated secretory phenotype (SASP), a marker of cellular senescence associated with biological aging, as the most highly up-regulated pathway in young women with PPCM or preeclampsia. Placentas from women with preeclampsia displayed multiple markers of amplified senescence and tissue aging, as well as overall increased gene expression of 28 circulating proteins that contributed to SASP pathway enrichment in serum samples from patients with preeclampsia or PPCM. The most highly expressed placental SASP factor, activin A, was associated with cardiac dysfunction or heart failure severity in women with preeclampsia or PPCM. In a murine model of PPCM induced by cardiomyocyte-specific deletion of the gene encoding peroxisome proliferator–activated receptor γ coactivator-1α, inhibiting activin A signaling in the early postpartum period with a monoclonal antibody to the activin type II receptor improved heart function. In addition, attenuating placental senescence with the senolytic compound fisetin in late pregnancy improved cardiac function in these animals. These findings link senescence biology to cardiac dysfunction in pregnancy and help to elucidate the pathogenesis underlying cardiovascular diseases of pregnancy.
Incidence of staff injury and illness at the Tokyo 2020 and Beijing 2022 Olympic and Paralympic Games
Larson, Emily G., Hasley, Ike B., Post, Eric G. , Cali, Malia G. , Clark, Stephanie C., McPherson, April L. , Noble-Taylor, Kayle E, Anderson, Travis , Anderson, Travis , Adams, William M , Noble-Taylor, Kayle E., Robinson, David M. , Finnoff, Jonathan T. , Adams, William M.

Mayo Clinic

BMJ Open Sport & Exercise Medicine | April 17, 2024 | Volume: 10 | Issue: 2 | Pages: e001835

10.1136/bmjsem-2023-001835 | PMID 38645762 Get It

Objective To report epidemiological data regarding injury and illness among the Team USA staff during the Tokyo 2020 Summer Olympic and Paralympic Games and Beijing 2022 Winter Olympic and Paralympic Games. Methods A retrospective review of all Team USA staff (total staff, N=1703 (62.5% female); total staff days (SD)=34 489) medical encounters during the Tokyo 2020 Games and Beijing 2022 Games was conducted. Details related to injury and illness were evaluated. Incidence with 95% CI per 1000 staff days were calculated. Results A total of 32 illnesses (incidence [95% CI] 0.9 [0.6, 1.2]) and 23 injuries (incidence 0.7 [0.4, 0.9]) were sustained by the Team USA delegation staff members during the Tokyo 2020 Games and Beijing 2022 Games. Female staff reported more illnesses (illnesses proportion (IP) 2.9%; incidence 1.4 [0.8, 2.0]), while male staff incurred more injuries (IP 1.8%; incidence 0.9 [0.5, 1.3]). When stratified by physiological system, dermatological and infectious were the most common systems involved with illness (IP 0.5%; incidence 0.2 [0.1, 0.4]). Injuries to the upper limb were most common (IP 0.3%; incidence 0.3 [0.1, 0.5]). Conclusion Injury and illness rates among the Team USA staff during the Tokyo 2020 Games and Beijing 2022 Games were low, but notable. Knowledge of injury and illness risks contributes to staffing decisions and prevention strategies for staff supporting athletes during competition.
Parents of children with Down syndrome reflect on their postnatal diagnoses, 2003–2022
Artal, Jonathan M. , Randall, Lindsey, Rubeck, Sabina , Allyse, Megan , Meredith, Stephanie , Skotko, Brian G. , Randall, Lindsey D. , Skotko, Brian G , Allyse, Megan A , Randall, Lindsey , Michie, Marsha , Riggan, Kirsten A.

Mayo Clinic

American Journal of Medical Genetics Part A | April 15, 2024 | Volume: 194 | Issue: 8 | Pages: No page available

10.1002/ajmg.a.63619 | PMID 38619097 Get It

Abstract A 2003 survey revealed the scope of mothers' dissatisfaction with their postnatal support following a diagnosis of Down syndrome (DS). Substantial proportions of mothers reported that providers conveyed diagnoses with pity, emphasized negative aspects of DS, and neglected to provide adequate materials explaining DS. This study follows up on the 2003 survey by assessing whether parents' experiences have improved. Four DS nonprofit organizations, which participated in the original study, distributed a mixed‐methods survey to families who have had children with DS between 2003 and 2022. Quantitative analysis assessed correlations among responses and differences between the 2003 and 2022 survey groups. Open‐ended responses were qualitatively analyzed. Compared to the 2003 findings, parents' perceptions of their postnatal care have not improved ( N = 89). Parents are increasingly likely to report that their providers pitied them, omitted positive aspects of DS, and provided insufficient materials describing DS. Substantial proportions of parents reported fear (77%) and anxiety (79%), only 24% described receiving adequate explanatory materials, and parents were 45% likelier to report that physicians discussed negative aspects of DS than positive aspects. Qualitatively, substantial numbers of parents recounted insensitive conduct by providers. These results suggest that despite interventions, parents' experiences of postnatal diagnoses of DS have not improved over time. Certain provider behaviors—such as describing positive aspects of DS and providing comprehensive explanatory materials—can reduce fear and anxiety, pointing to directions for reform.
Investigating Radiological Lag and the Temporal Evolution of MRI Lesions Within the Same Attack in MOGAD (S32.008)
Mankad, Kshitij , Krecke, Karl N. , Chen, John , Redenbaugh, Vyanka , Lopez, Alfonso, Sánchez, Cristina Valencia, Tillema, Jan‐Mendelt , Cacciaguerra, Laura , Abdel‐Mannan, Omar , Champsas, Dimitrios , Syc‐Mazurek, Stephanie B. , Hemingway, Cheryl , Ciccarelli, Olga , Pittock, Sean J. , Hacohen, Yael , Flanagan, Eoin P.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205834 Get It